Advantage Solutions (NASDAQ:ADV) reported quarterly sales of $981.10 million which missed the analyst consensus estimate of $981.32 million by 0.02 percent. This is a 15.43 percent increase over sales of $849.95 million the same period last year.
Oxford University PLATINUM Trial to Confirm Whether SIGA Technologies’ Tecovirimat is an Effective Treatment for Monkeypox
-Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/british-scientists-behind-key-covid-trial-launch-study-test-monkeypox-treatment-2022-08-23/
